liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers
Sahlgrens University Hospital.
Sahlgrens University Hospital.
Linköping University, Department of Medicine and Health Sciences, Cardiology . Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart Centre, Department of Cardiology.ORCID iD: 0000-0001-6353-8041
Rikshosp University Hospital.
Show others and affiliations
2010 (English)In: EUROPEAN JOURNAL OF HEART FAILURE, ISSN 1388-9842, Vol. 12, no 4, 404-410 p.Article in journal (Refereed) Published
Abstract [en]

Aims The aim of this study is to compare the effects of a 24 h intravenous infusion of levosimendan and a 48 h infusion of dobutamine on invasive haemodynamics in patients with acutely decompensated chronic NYHA class III- IV heart failure. All patients were receiving optimal oral therapy including a beta- blocker. Methods and results This was a multinational, randomized, double- blind, phase IV study in 60 patients; follow- up was 1 month. There was a significant increase in cardiac index and a significant decrease in pulmonary capillary wedge pressure (PCWP) at 24 and 48 h for both dobutamine and levosimendan. The improvement in cardiac index with levosimendan was not significantly different from dobutamine at 24 h (P = 0.07), but became significant at 48 h (0.44 +/- 0.56 vs. 0.66 +/- 0.63 L/min/m(2); P = 0.04). At 24 h, the reduction in the mean change in PCWP from baseline was similar for levosimendan and dobutamine, however, at 48 h the difference was more marked for levosimendan (23.6 +/- 7.6 vs. 28.3 +/- 6.7 mmHg; P = 0.02). No difference was observed between the groups for change in NYHA class, beta- blocker use, hospitalizations, treatment discontinuations or rescue medication use. Reduction in B-type natriuretic peptide (BNP) was significantly greater with levosimendan at 48 h (P = 0.03). According to physicians assessment, the improvement in fatigue (P = 0.01) and dyspnoea (P = 0.04) was in favour of dobutamine treatment, and hypotension was significantly more frequent with levosimendan (P = 0.007). No increase in atrial fibrillation or ventricular tachycardia was seen in either group. Conclusion A 24 h levosimendan infusion achieved haemodynamic and neurohormonal improvement that was at least comparable at 24 h and superior at 48 h to a 48 h dobutamine infusion.

Place, publisher, year, edition, pages
Oxford University Press , 2010. Vol. 12, no 4, 404-410 p.
Keyword [en]
Levosimendan, Dobutamine, Decompensated heart failure, Invasive monitoring
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-54864DOI: 10.1093/eurjhf/hfq032ISI: 000276049100017OAI: diva2:310850
Available from: 2010-04-16 Created: 2010-04-16 Last updated: 2013-09-26

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Dahlström, Ulf
By organisation
Cardiology Faculty of Health SciencesDepartment of Cardiology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 61 hits
ReferencesLink to record
Permanent link

Direct link